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Background: Previous research has shown posi-
tive effects from massage therapy (MT) for pre-
mature infants and for children with asthma,
arthritis, and other illnesses. Although these ef-
fects have been demonstrated, MT research on
children with cancer and blood disease is needed.
Purpose and Setting: The present study, con-
ducted at the Cancer Center, Shands Hospital,
at the University of Florida, Gainesville, meas-
ured the physical and psychological effects of MT
on pediatric oncology and hematology patients.
The participants were 30 children with cancer
or blood disease, ages 6 months to 17 years.
Research Design: This randomized, non-
blinded prospective study used measures of
physical health and mental wellbeing that were
completed before, during, and after four MT
sessions were implemented. Descriptive statis-
tics, one-way between-subjects analysis of vari-
ance, and an independent-samples t-test were
used to analyze the data.
Intervention: The treatment group received 20-
minute sessions of Swedish MT once daily for
approximately 4 days (inpatients), or once
weekly for approximately 4 weeks (outpatients);
the control group received no MT.
Results: Between-groups analyses indicated sig-
nificant psychological improvements for the MT
group on state anxiety (F1,58 = 16.79, p < 0.000),
trait anxiety (F1,58 = 3.95, p < 0.000), and emo-
tional state (F1,238 = 42.39, p < 0.001)]. Between-
groups analyses indicated significant physical
improvements for the MT group on muscle
soreness (F1,238 = 38.96, p < 0.001), discomfort
(F1,238 = 50.16, p < 0.001), respiratory rate
(F1,237 = 22.47, p < 0.000)], and overall progress
(t28 = 25.55, p < 0.000). No significant differences
were found between groups on parent-completed
ratings of their child’s physical or psychological
health, pulse rate, or blood pressure.
Conclusions: In children with cancer and blood
diseases, MT can reduce psychological and
physical distress and can have a positive effect
on quality of life.
KEYWORDS: Massage, pediatrics, palliative
therapy, oncology, hematology
Children with Cancer and Blood
Diseases Experience Positive
Physical and Psychological Effects
from Massage Therapy
INTRODUCTION
The American Cancer Society estimated 10,400
newly diagnosed pediatric cancer cases and 1545
deaths from cancer in children in 2007(1). Pediatric
cancer patients commonly experience adverse symp-
toms including nausea, physical pain, anxiety, depres-
sion, weight loss, and hair loss during treatment. As
providers seek affordable palliative treatment options
for pediatric patients, the use of complementary and
alternative modalities (CAM) such as massage
therapy (MT) is becoming popular. A study in 2003
reported that 33% of parents in a primary care setting
used CAM, with MT being most commonly pre-
ferred(2). Research findings indicate that MT can
improve circulation and immune function, dissolve soft
adhesions, reduce swelling, and relieve the pain and
stress associated with many illnesses(3–6). These out-
comes make palliative treatment with MT a viable
option for children with cancer and related blood dis-
eases such as hemophilia.
Although MT provides a promising option for chil-
dren with cancer, little data focus on this population of
oncology and hematology patients(5). However, related
research suggests that MT is an effective treatment
for other pediatric populations, including premature and
HIV-exposed newborns, and children with asthma,
cystic fibrosis, diabetes, and rheumatoid arthritis(3–11).
Documented outcomes include weight gain; reduced
levels of stress hormone; decreased anxiety, stress, and
depression; improved sleep; enhanced immune func-
tion; and reduced pain(3–11). Data from previous stud-
ies in various pediatric populations and settings provide
supportive evidence suggesting that children with can-
cer and related blood diseases will receive similar ben-
efits from MT.
Pain, a common adverse outcome associated with
cancer treatment, has been defined as “an unpleasant
sensory and emotional experience associated with ac-
tual or potential tissue damage, or described in terms
of such damage,” coupled with “the high prevalence
of painful neurological conditions”(12). Several chemo-
therapeutic agents can cause peripheral neuropathy, a
syndrome characterized by painful dysesthesia in the
hands and feet, with associated sensory, motor, and
autonomic deficits(12). Chronic pain can lead to dis-
ability, limited activity, and psychological problems.
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Increased pain perception is also correlated with higher
levels of anxiety and lower self-esteem(13). The rela-
tive resistance of neuropathic pain to medication justi-
fies the use of a modality such as MT(12,13).
A review of five non-pharmacologic strategies for
managing cancer pain in adults noted that MT promotes
relaxation, relieves muscle spasms, reduces pain and
swelling, increases blood circulation, decreases the
heart rate, and inhibits transmission of noxious stimuli
by stimulating large nerve fibers that reduce pain per-
ception(14). When used during chemotherapy treatment
in adult populations, MT has been found to reduce anxi-
ety, nausea, and stress; to enhance sleep; and to boost
the number and function of the immune system’s natu-
ral killer cells(15,16). If such improvements are repli-
cated in future research, MT can be justified as a viable
option of palliative care for pediatric cancer and blood
disease patients, promoting a greater focus on healing
and quality of life for these children.
The current study had three primary objectives:
• To determine the physiologic effects of MT in a
pediatric oncology and hematology population
• To determine the psychological effects of MT in a
pediatric oncology and hematology population
• To determine the feasibility of implementing MT
as a palliative treatment option in a cancer clinic
setting
The first two objectives led to the following study
hypotheses:
• Ha1: Children with cancer and blood diseases who
receive MT will experience beneficial physiologic
outcomes significantly more than will equivalent
children who do not receive MT.
• Ha2: Children with cancer and blood diseases who
receive MT will experience beneficial psychologi-
cal outcomes significantly more than will equiva-
lent children who do not receive MT.
METHODS
Participants
Using convenience sampling, resident physicians
chose 30 participants from a patient population in the
pediatric hematology and oncology division at the Can-
cer Clinic and Shands Hospital at the University of
Florida. Members of the control group (8 females, 7
males) and the treatment group (7 females, 8 males)
were aged 6 months to 17 years (mean: treatment—
10.7 years; control—9.3 years). There were 14 inpa-
tients (8 control, 6 treatment) and 16 outpatients (7
control, 9 treatment). Table 1 gives descriptive statis-
tics for the study participants. The diversity in age, dis-
ease, and inpatient or outpatient status was included to
represent the diverse patient population in this clinical
setting and to permit an evaluation of the feasibility of
implementing massage in the clinical setting while also
maximizing the external validity of the study. Partici-
pants received no compensation for their participation
in the study.
Design and Procedure
Potential participants were identified by physicians
and subsequently approached by an investigator, at
which time potential participants were informed about
the study process and any possible adverse effects and
benefits of the study. Consenting participants were
randomized into two groups by coin toss (“heads,” treat-
ment; “tails,” control) called by a witness in the pres-
ence of patient participants and their parents or
guardian. Consent forms were give to each participant
old enough to give consent and to the parents, parent,
or guardian to read and sign. The consent of the legal
guardian was obtained for all minors. Participants and
parents unable to read or to understand any part of the
consent form were given a verbal explanation. All par-
ticipants were volunteers and were treated according
to the ethical standards of the American Psychological
Association code of conduct(17).
Each participant was assigned a unique number to
ensure confidentiality. Treatment and control partici-
pants were assigned to one of two schedules of four
sessions each. Inpatients received daily sessions, and
outpatients received weekly sessions. Sessions were
conducted during regularly scheduled appointments in
a treatment room or the patient’s room within the clinical
setting. Treatment participants received 20 minutes of
Swedish MT including effleurage (gliding stroke), pe-
trissage (kneading), percussion (tapping with finger-
tips, palm, fist, or side of hand), compression (constant
pressure with hand or fists), and friction (deep circular
or vertical motion with fingertips). The MT was pro-
vided in the spots most comfortable for the participant,
most often on the hands, feet, arms, neck, back, and
shoulders. To ensure participant comfort, participants
were not required to disrobe for treatment. The hos-
pital robes worn by participants made for easy ac-
cess to bare hands, feet, arms, shoulders, and backs.
Covers were also provided, as in standard MT prac-
tice. The therapist (JH) is a nationally certified mas-
sage therapist, licensed in the State of Florida (where
study was conducted), with 5 years of experience in
the field of MT.
TABLE 1   Participant Descriptive Statistics
Group Sex (n) Mean age Status (n)
Male Female (years) Inpatient Outpatient
MT 8 7 10.7 6 9
Control 7 8 9.3 8 7
MT = massage therapy.HAUN et al.: EFFECTS FROM MASSAGE THERAPY
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A parent or legal guardian of the participant was present
during each treatment. At each session, the massage thera-
pist facilitated MT with the participants and thus pro-
vided a detailed demonstration for the parent or guardian,
enabling parents to possibly continue implementing treat-
ments at home; however, during the study, only the thera-
pist provided massage to participants. Attention was given
at all times to appropriate ethical procedures to ensure
the safety of the participants and the continued trust and
approval of the parents.
Before and after each session, the participant’s vi-
tal signs (collected by BS or clinical nursing staff),
discomfort level, and Faces muscle soreness and emo-
tional data were recorded by the research assistant
(BS). The research assistant (BS) collected the gen-
eral clinical progress scale after the second, third, and
fourth sessions. Participants or parents (or both) com-
pleted standardized measures [the State–Trait Anxiety
Inventory for Children (STAIC) and the Child Health
Questionnaire–Parent (CHQ-Parent)] before the first
and after the final session (collected by BS).
The data collection schedules were the same for
the treatment and control groups. Control participants
were seen in the same environment for the same pe-
riod of time for conversation and play with the thera-
pist. If control participants were not feeling well, the
therapist sat with them quietly.
Measures
Physiologic Measures
A Faces “My muscles feel ...” soreness scale with
assigned values ranging from 1 (“very sore”) to 5 (“very
good”) was used to assess muscle soreness before and
after each session. The pictorial Faces self-report re-
sponse scales have become increasingly popular for
evaluating clinical symptoms and have been found to
be valid and reliable for measuring pain-related symp-
toms in diverse pediatric settings(18–25).
Overall discomfort level was recorded before and
after each session on a scale from 0 to 4 (0 being “no
discomfort,” 4 being “maximal discomfort”). This
measure was collected as a verbal self-report, as is
commonly done in clinical settings such as the one in
which the present study was conducted.
Standard methods were used to assess the partici-
pants’ blood pressure, respiratory rate, and pulse rate
before and after each session.
The Child Health Questionnaire (CHQ)–Parent(26)
has two primary scales: physical health and psychologi-
cal health. It has been extensively validated in evalua-
tions of pediatric health status internationally(27–30). The
physical health scale was used to assess general health
physical function in study participants before and after
the series of sessions.
Psychological Measures
The CHQ–Parent psychological health scale was used
to assess general mental health in the study participants
before and after the series of sessions. The STAIC(31)
was used to record levels both of situational and of
characteristic anxiety (minimum score: 20; maximum
score: 60). The STAIC has been tested and extensively
validated in diverse pediatric populations internation-
ally(32–36,a). Spielberger and colleagues indicate that
the State–Trait Anxiety Inventory (STAI) and the STAIC
have been used in 8000 studies and have been trans-
lated into 58 languages and dialects(35).
A Faces “I feel ...” affective scale was used to
measure emotion, with a score ranging from 1 (“not
good at all”) to 5 (“very good”). As with the Faces
self-report pain scale, this pictorial scale has been
adapted and validated for measuring emotional symp-
toms in diverse pediatric settings(37–40).
General Clinical Measure
A general clinical progress measure was collected
at the end of the second, third, and fourth sessions to
assess progress at each treatment or control session.
This verbal self-report measure was rated on a scale
from 0 to 10 (0 = no progress; 10 = maximal progress).
Progress was defined as “feeling better overall, mus-
cles and body feeling better, with less pain, and calmer
with less tension.” This measure was used as a verbal
self-report, commonly collected and documented in
patient records—that is, clinical SOAP (subjective data,
objective data, assessment, and plan) notes.
If participants were unable to respond because of
age or illness, parent reports were collected in lieu of
the self-reports, consistent with common practice in
clinical settings(41–49). There are constraints related
to such parent-proxy reports, but Varni et al. suggest
that although “pediatric patient self-report is advo-
cated, there remains a fundamental role for parent
proxy-report in pediatric clinical trials and health serv-
ices research”(49).
Data Analysis
Statistical analyses were conducted to evaluate the
mean differences between the treatment group and the
control group. For measures collected before and after
each session, including the Faces scales, discomfort
scale, and vital signs, the differences between the
groups were examined using a 2 (treatment) × 4 (time)
one-way between-subjects analysis of variance
(ANOVA). Additionally, 2 (treatment) × 2 (time) one-
way between-subjects ANOVAs were used to com-
pare group mean scores for the STAIC and
CHQ–Parent measures taken before and after the se-
ries of sessions. Post hoc analyses using a Scheffe
multiple comparisons test were conducted to identify
a Kirisci L, Clark DB. Reliability and validity of the State–Trait
Anxiety Inventory for children in an adolescent sample: con-
firmatory factor analysis and item response theory. Data pre-
sented at the Annual Meeting of the American Educational
Research Association; New York, New York; April 8–12, 1996.HAUN et al.: EFFECTS FROM MASSAGE THERAPY
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the source of significant differences. Because of the
use of a mean composite score calculated for overall
progress, an independent-samples t-test was used to
determine any differences between the treatment and
control groups in self-reported progress across the se-
ries of four sessions. Statistical significance was set at
p ≤ 0.05.
RESULTS
Physiologic Measures
Faces “My Muscles Feel ...” Scale
No significant difference was observed between
treatment and control groups before treatment. How-
ever, significant mean differences on the scale of muscle
soreness were found between the groups after treatment
(F1,28 = 148.20, p < 0.001), such that members of the
treatment group reported significantly less post-
treatment muscle soreness than did members of the
control group. Scheffe comparisons indicated that the
mean values of the muscle soreness scores in the treat-
ment group increased significantly (indicating positive
change) and that no significant change occurred in the
control group scores. Table 2 provides pre- and post-
session means and standard deviations both for the
treatment group and for the control group.
Discomfort Level
We observed no significant difference in discom-
fort between the two groups before treatment, but sig-
nificant differences between group means were
indicated after treatment (F1,238 = 50.16, p < 0.001),
TABLE 2   Study Outcome Scores for the Treatment and Control Groups
Measure and Groupa Pre-session score Post-session score db
[mean (SD)] [mean (SD)]
Physiologic outcomes
Faces Muscle Soreness Scale
MT 3.06 (0.56) 4.53 (0.34)
3.03 Control 3.18 (0.65) 3.15 (0.57)
Discomfort level
MT 1.90 (0.50) 0.13 (0.28) 3.38
Control 1.93 (0.76) 1.92 (0.78)
Respiratory rate (breaths/min)
MT 21.20 (1.82) 17.93 (1.87) 1.68
Control 21.80 (3.08) 21.6 (2.50)
Pulse (beats/min)
MT 96.80 (17.30) 92.58 (17.73) 0.14
Control 95.02 (24.07) 95.62 (26.71)
Systolic blood pressure (mmHg)
MT 112.75 (12.21) 116.20 (16.32) 0.07
Control 114.55 (13.97) 117.25 (14.64)
Diastolic blood pressure (mmHg)
MT 63.60 (10.75) 64.07 (10.24) –0.04
Control 62.63 (11.94) 63.57 (12.80)
CHQ–Parent, physical health scale
MT 25.01 (9.55) 19.08 (11.99) 0.51
Control 25.01 (11.41) 24.91 (10.98)
Psychological outcomes
CHQ–Parent, psychological health scale
MT 43.80 (8.35) 46.51 (9.10) 0.30
Control 42.37 (3.76) 43.98 (7.75)
State Anxiety Inventory for Children
MT 33.87 (6.82) 23.00 (2.83) 2.55
Control 35.93 (8.08) 37.73 (8.73)
Trait Anxiety Inventory for Children
MT 32.87 (5.42) 27.73 (2.94) 1.98
Control 34.07 (5.12) 37.33 (6.77)
Faces Emotion Scale
MT 3.33 (0.49) 4.82 (0.42) 3.33
Control 3.35 (0.50) 3.27 (0.51)
a  n = 15 for each group.
b  Values are between-groups standardized mean effect sizes; a positive value indicates a better outcome for the MT group.
SD = standard deviation; MT = massage therapy; CHQ = Child Health Questionnaire.HAUN et al.: EFFECTS FROM MASSAGE THERAPY
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such that the treatment group reported significantly less
discomfort than did the control group. Scheffe com-
parisons showed that the mean values of the treated
group’s discomfort level scores declined significantly,
but that no significant change occurred in the control
group scores. Table 2 provides pre- and post-session
means and standard deviations both for the treatment
group and for the control group.
Vital Signs
We observed no significant difference between the
groups in pulse rate (F1,238 = 0.049, p < 0.825) or in
systolic (F1,238 = 0.593, p < 0.442) and diastolic blood
pressure (F1,238 = 0.246, p < 0.620), before or after
treatments. However, MT affected respiratory rate
(F1,237 = 22.47, p < 0.000), such that, post treatment,
the rate declined significantly in the treatment group
as compared with the control group. Scheffe compari-
sons indicated that the mean values of the treated group’s
respiratory rate declined significantly; no significant
change was observed in the scores for the control group.
Table 2 provides pre- and post-session means and stand-
ard deviations both for the treatment group and for the
control group.
CHQ–Parent, Physical Scale
On the CHQ–Parent questionnaire, we found no sig-
nificant differences between the treatment and control
groups for physical health, before or after treatments
(F1,58 = 1.05, p = 0.310). Table 2 provides pre- and
post-session means and standard deviations both for
the treatment group and for the control group.
Psychological Measures
CHQ–Parent, Psychological Scale
On the CHQ–Parent questionnaire, we found no sig-
nificant differences between the treatment and control
groups for psychological health, before or after treat-
ments (F1,58 = 1.06, p = 0.308). Table 2 provides pre-
and post-session means and standard deviations both
for the treatment group and for the control group.
State Anxiety Inventory for Children
We observed no group difference in the State Anxi-
ety Inventory for Children before treatment. Post-treat-
ment levels of state anxiety were lower in the treatment
group than in the control group (F1,58 = 16.79, p < 0.000).
Scheffe comparisons indicated that the mean values
of the state anxiety scores in the treatment group de-
clined significantly; no significant change occurred in
the scores for the control group. Table 2 provides pre-
and post-session means and standard deviations both
for the treatment group and for the control group.
Trait Anxiety Inventory for Children
We observed no significant difference between the
two groups in the Trait Anxiety Inventory for Children
before treatments, but a significant treatment effect
was evident for the treatment group as compared with
the control group after the series of sessions (F1,58 =
13.95, p < 0.000), such that the treatment group re-
ported significantly decreased trait anxiety. The control
group reports showed no significant change. Scheffe
comparisons indicated that the mean values of the trait
anxiety scores declined significantly in the treatment
group; no significant change was observed in the scores
for the control group. Table 2 provides pre- and post-
session means and standard deviations both for the
treatment group and for the control group.
Faces Emotion “I Feel ...” Scale
The treatment and control groups showed no sig-
nificant differences in their Faces “I Feel ...” scores
before treatment. However, post-treatment, the treat-
ment and control group means showed significant dif-
ferences (F1,238 = 42.39, p < 0.001), such that the
treatment group reported feeling significantly better,
and the control group reported no significant change.
Scheffe comparisons indicated that the mean values
of the emotion scores in the treatment group improved
significantly. We observed no significant change in the
scores for the control group. Table 2 provides pre- and
post-session means and standard deviations both for
the treatment group and for the control group.
General Clinical Progress Scale
We found significant differences in the mean
progress scores between the treatment and control
groups (t28 = 25.55, p < 0.001). The treatment group
reported significant progress after the treatment series;
the control group reported no change. Mean value
[standard deviation (SD)] for the control group was 0.49
(0.87); for the treatment group, it was 8.62 (0.87).
DISCUSSION
Research into MT in the area of pediatric oncology
and hematology is limited. The present study was con-
ducted to examine the physiologic and psychological
effects of MT on children with cancer and blood dis-
eases. Our findings indicate a general improvement in
physical and psychological well-being that supports both
hypotheses posited in this study—findings that are largely
consistent with those reported in related research(4–7,14).
As seen in other cancer populations, the findings in
this study are consistent with the positive rehabilita-
tive effect of MT(5,6,14). Physiologic measures suggest
that MT reduced muscle soreness, discomfort, and
respiratory rate. Psychological measures indicate that
MT reduced state and trait anxiety and positively in-
fluenced overall emotional well-being, and they support
prior findings that indicate that lasting psychological
effects result from MT(3,5–8). Additionally, the general
clinical progress found in the treatment group suggests
that MT can provide a general improvement in quality
of life.HAUN et al.: EFFECTS FROM MASSAGE THERAPY
12
INTERNATIONAL JOURNAL OF THERAPEUTIC MASSAGE AND BODYWORK—VOLUME 2, NUMBER 2, JUNE 2009
In relating measure outcomes, participants who re-
ceived MT experienced a significant reduction in mus-
cle soreness and discomfort that corresponded with
slowed respiration, improvement in emotional state,
and overall progress. The combination of muscle re-
laxation and decreased anxiety suggest that MT can
induce a general sense of relaxation for recipients.
Considered together, these psychophysiologic effects
indicate that MT could also promote optimal immune
system functioning, although the current study does not
examine that effect directly. Current findings also in-
dicate that MT can be effectively implemented within
an oncology setting and can provide significant pallia-
tive benefits to pediatric recipients across a diverse
age range and disease population. The results indicate
that clinicians, parents, and other caregivers should
consider MT a viable palliative intervention for symp-
tom relief in children with cancer and blood disease.
It should be noted that, because parents or guard-
ians were present for each child’s treatments (which
could serve as demonstrations of how MT can be pro-
vided), it is possible they may have spontaneously pro-
vided additional MT to outpatient participants in the
home setting. Data concerning this possibility were not
collected in the current study. We recommend that fu-
ture pediatric studies collect such data from parents or
guardians to account for potential confounding effects.
Further, bias may have occurred in self-reports from
the participants or their parents (or both) because of
expectancy or social desirability effects. Finally, this
pilot study did not collect data on symptoms such as
nausea, headaches, and pain around access portals,
although many participants reported a decrease in such
symptoms. These validity threats should be addressed
in subsequent studies.
Our pilot study needs to be replicated in a larger
sample of patients that would allow for subgroup analy-
sis by age, diagnosis, stage and severity of disease,
and inpatient or outpatient status. A larger study might
also examine the effects of MT on a diverse range of
symptomology. Further, a larger study would also al-
low for more robust complex multivariate statistical
analyses and, potentially, broader generalization of
the findings.
CONCLUSIONS
The findings of this pilot study suggest that MT can
be effectively implemented for pediatric oncology and
hematology patients within the clinical setting to re-
duce adverse physical and psychological symptoms as-
sociated with cancer treatment and cancer pain. The
successful recruitment and implementation in inpatient
and outpatient recipients alike suggest that positive out-
comes associated with MT can be achieved both for
oncology and for hematology pathologies, for girls and
for boys, in a wide range of age groups, in diverse clini-
cal environments. Although cancer clinics and oncology/
hematology wards are hectic clinical settings that must
provide necessarily invasive clinical care such as
chemotherapy, which clearly comprises the immune
system, our data suggest that the addition of MT as a
palliative treatment can increase quality of life and the
health of pediatric oncology and hematology patients.
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